Boston Tech
Agios Posted New Sickle Cell Data, and Cambridge Gets a Rare Clean Win
Agios unveiled detailed Phase 3 sickle cell data on June 13, 2026, giving Cambridge biotech a real win in a field where progress is hard to earn.
Boston Tech
Roche Bought PathAI, So Boston Tech Is Allowed to Strut for One Whole Minute
Roche is buying Boston-based PathAI for $750M upfront plus milestones, and yes, this is exactly the kind of hard-tech, health-AI win Boston should be insufferably proud of.
Startups
Helical’s $10M Seed Wants a Virtual AI Lab for Pharma — Finally, a Wet-Lab Hall Pass
Helical just raised $10M to turn bio foundation models into a virtual pharma lab. The pitch is grand, but this one might actually earn the pipettes.
Deals
IO Biotech Discovers the Strategic Alternative Is “Hiring a Banker”
IO Biotech (Nasdaq: IOBT) cost containment, workforce reduction, and the soft language of biotech distress.
Launch
This New Tokyo Microscope Ends 400 Years of Cellular Guesswork
Tokyo’s new “Great Unified Microscope” sees micro and nano worlds at once—finally showing cells can’t hide their secrets anymore.
Biotech
Nomic Bio’s nELISA Tech Makes Proteomics Scalable, and Surprisingly Cool
Nomic Bio publishes its nELISA proteomics platform in Nature Methods, unveiling a 1.4 million–protein dataset and a browser-based Nomic Portal. Here’s why that actually matters — and how it could reshape drug discovery.